Probióticos. Algunas consideraciones sobre su empleo antes, durante y después de la infección por SARS-CoV-2.

Gissel García Menéndez

Texto completo:

PDF

Resumen

Los probióticos son microorganismos vivos que, administrados a un hospedero en formas y cantidades adecuadas, mejoran o restauran la microbiota intestinal y, consecuentemente, sus funciones metabólicas e inmunológicas. Estas formulaciones han sido empleadas en la prevención, tratamiento y recuperación de secuelas de enfermedades infecciosas. Partiendo de esos presupuestos, y teniendo en cuenta la necesidad de desarrollar nuevas aproximaciones terapéuticas para el enfrentamiento de la infección por SARS CoV-2, se hace una revisión de las potencialidades del uso de esas bacterias saludables en la prevención, tratamiento y recuperación de secuelas de esa virosis.

Palabras clave

SARS-CoV-2, COVID-19, Probióticos, profilaxis, tratamiento

Referencias

Maldonado Galdeano C, Inés Cazorla SI, Lemme Dumit JM, Véleza E, Perdigón G. Beneficial Effects of Probiotic Consumption on the Immune System. Annals Nutricion and Metabolism 2019;74:115-24.

Gibson GR, Hutkins R, Sanders ME, Prescott SL, Reimer RA, Salminen SJ, et al. Expert consensus document .The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics. Nature Reviews | Gastroenterology & Hepatology. 2017:1-14.

Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, et al. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases. 2020;94:91-5.

WHO. Coronavirus press conference 11 February, 2020. Geneva: World Health Organization2020. Available from: https://www.who.int/docs/defaultsource/coronaviruse/transcripts/who-audio-emergencies-coronavirus-fullpress-conference-11feb2020-final.pdf?sfvrsn=e2019136_2.

WHO. Virtual press conference on COVID-19 11 March 2020 2020. Available from: http://www.who.int.

COVID-19 Coronavirus Pandemic2020. Available from: http://www.worldometer.info.cor.

MINSAP. Coronavirus en Cuba, 11 de agosto de 2020. Sitio Oficial del Gobierno del ministerio de Salid Publica [Internet]. 2020. Available from: http://salud.msp.gob.cu.

Rabi FA, Zoubi MSA, Kasasbeh GA, Salameh DM, Al-Nasser AD. SARS-CoV-2 and coronavirus disease 2019: what we know so far. Pathogens 2020.;9:1-14.

Cao X. COVID-19: immunopathology and its implications for therapy. Nature Reviews Immunology. 2020;20:269-70.

Wang Y, Wang Y, Chen Y, Qin Q. Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID-19) implicate special control measures. Journal of Medical Virology. 2020;92:.568-76.

Fulop T, Larbi A, Dupuis G, Le Page A, Frost EH, Cohen AA, et al. Immunosenescence and Inflamm-Aging As Two Sides of the Same Coin: Friends or Foes? Frontiers in immunology. 2017;8:1960.

Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, et al. Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2020;71(15):762-8.

Galeotti C, Bayry J. Autoimmune and inflammatory diseases following COVID-19. Nature Reviews Rheumatology. 2020;16(8):413-4.

Demertzis ZD, Dagher C, Malette KM, Fadel RA, Bradley PB, Brar I, et al. Cardiac sequelae of novel coronavirus disease 2019 (COVID-19): a clinical case series. European Heart Journal - Case Reports. 2020.

Fiani B, Covarrubias C, Desai A, Sekhon M, Jarrah R. A Contemporary Review of Neurological Sequelae of COVID-19. Front Neurol. 2020;11:640-.

Wu Q, Zhou L, Sun X, Yan Z, Hu C, Wu J, et al. Altered Lipid Metabolism in Recovered SARS Patients Twelve Years after Infection. 2017.

Enaud R, Prevel R, Ciarlo E, Beaufils F, Wieërs G, Guery B, et al. The Gut-Lung Axis in Health and Respiratory Diseases: A Place for Inter-Organ and Inter-Kingdom Crosstalks. Front Cell Infect Microbiol. 2020;10:9-.

Dhar D, Mohanty A. Gut microbiota and Covid-19- possible link and implications. Virus Res. 2020;285:198018-.

Maldonado Galdeano C, de Moreno de LeBlanc A, Vinderola G, Bibas Bonet ME, Perdigon G. Proposed Model: Mechanisms of Immunomodulation Inducedby Probiotic Bacteria. CLINICAL AND VACCINE IMMUNOLOGY, . 2007;14(5):485-92.

Hosainzadegan H. Gut Microbiota and Metabolic Syndrome (Diabetes). Annals of Short Reports [Internet]. 2019; 2:[1040 p.].

Isolauri E, Sütas Y, Kankaanpää P, Arvilommi H, Salminen S. Probiotics: effects on immunity. The American Journal of Clinical Nutrition. 2001;73(2):444s-50s.

Kalam Azad A, Sarker M, Wan D. Immunomodulatory Effect s of Probiotics on Cytokine Profiles. Biomed Res Int. 2018:1-10.

Sivamaruthi B, Kesika P, Chaiyasut C. A review on anti-aging properties of probiotics. International Journal of Applied Pharmaceutics. 2018;10:23-7.

Baud D, Dimopoulou Agri V, Gibson GR, Reid G, Gionnoni E. Using probiotics to flatten the curve of coronavirus disease COVID-2019 pandemic. . Frontiers of Public Health. 2020;8(186).

Huang Y, Mao K, Chen X, Sun M-A, Kawabe T, Li W, et al. S1P-dependent interorgan trafficking of group 2 innate lymphoid cells supports host defense. Science. 2018;359(6371):114-9.

Ichinohe T, Pang IK, Kumamoto Y, Peaper DR, Ho JH, Murray TS, et al. Microbiota regulates immune defense against respiratory tract influenza A virus infection. Proceedings of the National Academy of Sciences of the United States of America. 2011;108(13):5354-9.

Lin L, Jiang X, Zhang Z, Huang S, Zhang Z, Fang Z, et al. Gastrointestinal symptoms of 95 cases with SARS-CoV-2 infection. Gut. 2020;69(6):997.

Ng SC, Tilg H. COVID-19 and the gastroitestinal tract: more than meets the eye. Gut. 2020;69: 973-4.

Pan Y, Zhang D, Yang P, Poom LM, Wan Q. Viral load of SARS-CoV-2 in clincal samples. Lancet Infection Disease. 2020;20(411-2).

Hashimoto T, Perlot T, Rehman A, Trichereau J, Ishiguro H, Paolino M, et al. ACE2 links amino acid malnutrition to microbial ecology and intestinal inflammation. Nature. 2012;487(7408):477-81.

Lehtoranta L, Pitkäranta A, Korpela R. Probiotics in respiratory virus infections. Eur J Clin Microbiol Infect Dis. 2014;33(8):1289-302.

Giannoni E, Baud D, Dimopoulou Agri V, Gibson GR, Reid G. Probiotics and COVID-19. Correspondence [Internet]. 2020; 5:[720-1 pp.]. Available from: www.thelancet.com/gastrohep

Mak JWY, Chan FKL, Ng SC. Probiotics and COVID-19: one size does not fit all. Lancet Gastroenterol Hepatol. 2020;5(7):644-5.

Gu S, Chen Y, Wu Z, Chen Y, Gao H, Lv L, et al. Alterations of the Gut Microbiota in Patients With Coronavirus Disease 2019 or H1N1 Influenza. Clinical Infectious Diseases. 2020.

Enlaces refback

  • No hay ningún enlace refback.


Bookmark and Share


Licencia de Creative Commons
Esta obra está bajo una licencia de Creative Commons Reconocimiento-NoComercial-CompartirIgual 4.0 Internacional.